Search research articles
Contact Us
Filters
Showing results (901-910 of 920) with videos related to
Page
of 92
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 1, 2022
Efficacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b Study
Yuankai Shi, Shiman Wu, Ke Wang, et al.
Cell Reports. Medicine
|
May 7, 2025
Genetic biomarker study of sunvozertinib for clinical prognosis and prediction in NSCLC with EGFR exon 20 insertion mutation
Yan Xu, James Chih-Hsin Yang, Yanqiu Zhao, et al.
Journal for Immunotherapy of Cancer
|
November 28, 2024
Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study
Caicun Zhou, Gongyan Chen, Yunchao Huang, et al.
Lancet (London, England)
|
May 31, 2026
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China
Shun Lu, Baogang Liu, Yongzhong Luo, et al.
Lancet (London, England)
|
October 22, 2025
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
Zhiwei Chen, Fang Yang, Zhou Jiang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 9, 2025
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)
James Chih-Hsin Yang, Mengzhao Wang, Ludovic Doucet, et al.
The Lancet. Respiratory Medicine
|
February 6, 2025
Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 study
Yuankai Shi, Yanzhen Guo, Xingya Li, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 16, 2023
Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial
Caicun Zhou, Gongyan Chen, Yunchao Huang, et al.
Lung Cancer (Amsterdam, Netherlands)
|
May 10, 2023
Central nervous system efficacy of rezivertinib (BPI-7711) in advanced NSCLC patients with EGFR T790M mutation: A pooled analysis of two clinical studies
Sheng Yang, Shiman Wu, Yanqiu Zhao, et al.
Frontiers in Oncology
|
October 12, 2020
Survival Benefit and Genetic Profile of Pemetrexed as Initial Chemotherapy in Selected Chinese Patients With Advanced Lung Adenocarcinoma
Long-Hua Guo, Ming-Feng Zhang, He-Long Zhang, et al.
Page
of 92
Search research articles
Search
Showing results (901-910 of 920) with videos related to
Sort By:
Page
of 92
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 1, 2022
Efficacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b Study
Yuankai Shi, Shiman Wu, Ke Wang, et al.
Cell Reports. Medicine
|
May 7, 2025
Genetic biomarker study of sunvozertinib for clinical prognosis and prediction in NSCLC with EGFR exon 20 insertion mutation
Yan Xu, James Chih-Hsin Yang, Yanqiu Zhao, et al.
Journal for Immunotherapy of Cancer
|
November 28, 2024
Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study
Caicun Zhou, Gongyan Chen, Yunchao Huang, et al.
Lancet (London, England)
|
May 31, 2026
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China
Shun Lu, Baogang Liu, Yongzhong Luo, et al.
Lancet (London, England)
|
October 22, 2025
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
Zhiwei Chen, Fang Yang, Zhou Jiang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 9, 2025
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)
James Chih-Hsin Yang, Mengzhao Wang, Ludovic Doucet, et al.
The Lancet. Respiratory Medicine
|
February 6, 2025
Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 study
Yuankai Shi, Yanzhen Guo, Xingya Li, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 16, 2023
Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial
Caicun Zhou, Gongyan Chen, Yunchao Huang, et al.
Lung Cancer (Amsterdam, Netherlands)
|
May 10, 2023
Central nervous system efficacy of rezivertinib (BPI-7711) in advanced NSCLC patients with EGFR T790M mutation: A pooled analysis of two clinical studies
Sheng Yang, Shiman Wu, Yanqiu Zhao, et al.
Frontiers in Oncology
|
October 12, 2020
Survival Benefit and Genetic Profile of Pemetrexed as Initial Chemotherapy in Selected Chinese Patients With Advanced Lung Adenocarcinoma
Long-Hua Guo, Ming-Feng Zhang, He-Long Zhang, et al.
Page
of 92